According to filings with the U.S. Securities and Exchange Commission, Osteal Therapeutics is raising up to $49,999,999.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, David Thompson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Osteal Therapeutics
Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences. Osteal Therapeutics employs a low risk development strategy by improving delivery of pharmaceuticals with long histories of safety and efficacy. The company is lead by a highly experienced team of orthopedic industry veterans supported by world-class clinical partners. The lead product under development, VT-X7, is a drug-device combination product that has the potential to be the first FDA approved antibiotic therapy for local delivery to treat infected joint prosthesis. If approved, VT-X7 has the potential to improve outcomes and lower the cost of care for orthopedic surgeons and their patients by providing a faster, more reliable treatment option. VT-X7 has undergone extensive pre-clinical development and successfully completed a Phase 2 clinical trial in late 2020.

To learn more about Osteal Therapeutics, visit http://www.ostealtx.com/
Company Linkedin Page: https://www.linkedin.com/company/osteal/

Contact:
David Thompson, Chief Executive Officer
469-809-2630
https://www.linkedin.com/in/david-p-thompson3/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.